Navigation Links
InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR '09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
Date:5/21/2009

BARCELONA, Spain, May 20 /PRNewswire/ -- InspireMD, Ltd. announced today the completion of enrolment for the MAGICAL trial (MGuard(TM) in Acute Myocardial). The trial was designed to confirm the clinical feasibility, safety and performance of MGuard when used during Primary PCI in STEMI patients.

The MAGICAL trial is a multicenter, prospective, single arm, 60 patients study (Principal investigator: Dr. Dariusz Dudek, Jagiellonian University, Krakow, Poland). Primary end-points are incidence of complete ST segment resolution measured 60 minutes post procedure and incidence of TIMI 3 flow after PCI. Main secondary endpoints are myocardial blush grade and MACE (major adverse cardiac events) at discharge, 30 days and 6 months.

"I am very pleased and excited we reached this milestone" said Dr. Dariusz Dudek, the MAGICAL Study Chief Investigator, from Jagiellonian University in Krakow. "From the data collected so far, primary PCI for STEMI patients using MGuardTM seems highly safe and effective".

To date, TIMI flow 3 is 91%, MBG 3 (Myocardial Blush Grade) is 74%, Complete ST Resolution is 63%. MACE at discharge is 0% and 30 days MACE to date is 0% as well.

"This important milestone is getting us closer to confirm MGuard's important role in the treatment of acute MI patients, by providing a comprehensive solution to the distal embolization threat" said Eli Bar, CTO and VP R&D at InspireMD. "So far, the MAGICAL Trial results are confirming what we had experienced in cath-labs around the world; that the MGuardTM performs well and delivers extra safety for the patients".

A presentation of the updated results of the MAGICAL trial by Dr. Dariusz Dudek will be given at the InspireMD Cocktail Reception, May 21st at 18:30 at the Hilton Diagonal Mar, next to the EuroPCR conference CCIB Conference center. The Cocktail Reception and Debate: "What is the Best Strategy in Acute M
'/>"/>

SOURCE InspireMD
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
2. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
3. Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
4. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
5. Martek to Announce Second Quarter 2009 Results
6. Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil
7. The Hamner Institutes Announce Partnership With China Medical City
8. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
9. Beckman Coulter, Inc. Announces Pricing of Common Stock Offering
10. MedClean Technologies, Inc. Announces Private Offer to Exchange Warrants
11. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
(Date:7/10/2014)... Senior supply chain management executives from over ... challenges of “Reducing Cost, Lead Time, & Defects in ... Describing the partnership of the Bio Supply Management Alliance ... ( SCMI) of the University of San Diego ... Kroc Institute of Peace and Justice in San Diego, ...
(Date:7/10/2014)... , July 10, 2014 On ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique project ... project BIOCAD develops a number of innovative drugs based ... diseases. The ceremony took place at the International Exhibition ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- ... and interpretation, today announced an agreement with ... analytics for Lineagen,s NextStep Dx PLUS.  ... neurodevelopmental and neurological disorders, currently offers FirstStep ... (CMA) testing service used by healthcare providers ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... somehow survived where other traditional marketing tools and old ... must face harsher realities once again, all to ensure ... Web sites are simply doomed. While billions of Web ... clash into the billions of surfing customers and simply ...
... Ted Kanavas, R-Brookfield, called on the Legislature and the ... Development Fund. , ,The fund would use existing information ... Administration and segregate a portion of the funds for ... would not flow into this fund. , ,This fund ...
... Corporation and First Data Corporation jointly ... provides for the purchase of substantially all of the ... approximately $610 million in cash. As the majority shareholder ... million and NYCE will become a Metavante subsidiary. , ...
Cached Biology Technology:The mysteries and the future of Web sites 2The mysteries and the future of Web sites 3The mysteries and the future of Web sites 4Metavante and First Data to buy PIN-debit company NYCE 2
(Date:7/11/2014)... that under the normal circumstances, astrocytes participate ... neuronal environment, and exhibit therapeutic and repairing ... Previous studies have found that nerve cells ... induction have reduced viability, which produces influences ... Yuan, Kailuan General Hospital, Hebei United University, ...
(Date:7/11/2014)... Rio de Janeiro, Brazil- In the brains of ... mechanism that allows an electric or chemical signal ... another. Chemical synapses, which are the most abundant ... inhibitory. Synapse formation is crucial for learning, memory, ... and inhibitory synapses critical for brain function. ...
(Date:7/10/2014)...  Aware, Inc. (NASDAQ: AWRE ), a ... on June 26, 2014 that its Board of Directors ... share, or approximately $40 million in total.  The Board ... a payment date of July 24, 2014.  The Company ... an ex-dividend date for this special cash dividend.  An ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... President and Scientific Director and Director of the Hematopoiesis ... cliniques de Montral (IRCM), and his team was recently ... the American Society of Hematology. The researchers found that ... cells, which could lead to a better treatment for ...
... University of California, Riverside Bourns College of Engineering ... recently awarded a five-year, $6.25 million grant to ... for soldiers increasingly reliant on electronic devices. ... department of environmental and chemical engineering, and researchers ...
... Amid growing concern that synthetic life sciences pose biosecurity ... DNA sequence trade. Research published today in the ... looks at the necessity of a global regulator for ... Synthetic life sciences are making breakthroughs at a ...
Cached Biology News:A scientific breakthrough could be the first step in a better treatment for leukemia patients 2Research aims to lighten load carried by soldiers 2Technology to screen for synbio abuses lags 2Technology to screen for synbio abuses lags 3